The cellular immune response against Epstein-Barr virus decreases during ocrelizumab treatment

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Stephen L. Hauser, Amit Bar‐Or, Gavin Giovannoni et al. · New England Journal of Medicine · 2016 · 1.9K citations · Full text

Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity

John B. Harley, Xiaoting Chen, Mario Pujato et al. · Nature Genetics · 2018 · 402 citations

Transcriptional Regulation, Autoimmune Disease, Allergy +9

T helper 17.1 cells associate with multiple sclerosis disease activity: perspectives for early intervention

Jamie van Langelaar, Roos M. van der Vuurst de Vries, Malou Janssen et al. · Brain · 2018 · 209 citations · Full text

Inflammation, Cytokine, Autoimmune Disease +15

Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis

Michael P. Pender, Peter A. Csurhes, Corey Smith et al. · JCI Insight · 2018 · 153 citations · Full text

Attenuated immune control of Epstein–Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA‐DR15

Hana Zdimerova, Anita Murer, Christine Engelmann et al. · European Journal of Immunology · 2020 · 103 citations